Hunter Associates Investment Management’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-22,000
| Closed | -$12K | – | 248 |
|
|
2024
Q4 | $12K | Sell |
22,000
-1,000
| -4% | -$545 | ﹤0.01% | 253 |
|
|
2024
Q3 | $22K | Hold |
23,000
| – | – | ﹤0.01% | 257 |
|
|
2024
Q2 | $22K | Hold |
23,000
| – | – | ﹤0.01% | 252 |
|
|
2024
Q1 | $37K | Hold |
23,000
| – | – | 0.01% | 257 |
|
|
2023
Q4 | $19K | Sell |
23,000
-1,000
| -4% | -$826 | ﹤0.01% | 257 |
|
|
2023
Q3 | $20K | Sell |
24,000
-1,500
| -6% | -$1.25K | ﹤0.01% | 249 |
|
|
2023
Q2 | $24K | Hold |
25,500
| – | – | ﹤0.01% | 248 |
|
|
2023
Q1 | $28K | Sell |
25,500
-1,500
| -6% | -$1.65K | 0.01% | 254 |
|
|
2022
Q4 | $38K | Sell |
27,000
-1,500
| -5% | -$2.11K | 0.01% | 227 |
|
|
2022
Q3 | $31K | Hold |
28,500
| – | – | 0.01% | 215 |
|
|
2022
Q2 | $49K | Buy |
28,500
+8,500
| +43% | +$14.6K | 0.01% | 218 |
|
|
2022
Q1 | $41K | Buy |
20,000
+9,000
| +82% | +$18.5K | 0.01% | 140 |
|
|
2021
Q4 | $41K | Buy |
+11,000
| New | +$41K | 0.01% | 151 |
|
|
2021
Q2 | – | Sell |
-15,825
| Closed | -$84K | – | 140 |
|
|
2021
Q1 | $84K | Buy |
+15,825
| New | +$84K | 0.02% | 201 |
|